Akers Biosciences (AKER) Stock Price, Forecast & Analysis

NASDAQ:AKER

2.47
-0.26 (-9.52%)
At close: Apr 16, 2021
2.43
-0.04 (-1.62%)
After Hours: 4/16/2021, 9:50:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AKER Key Statistics, Chart & Performance

Key Statistics
Market Cap41.13M
Revenue(TTM)N/A
Net Income(TTM)-17.58M
Shares16.65M
Float16.65M
52 Week High6.97
52 Week Low1.65
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.25
PEN/A
Fwd PEN/A
Earnings (Next)02-28
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
AKER short term performance overview.The bars show the price performance of AKER in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

AKER long term performance overview.The bars show the price performance of AKER in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of AKER is 2.47 null. In the past month the price decreased by -29.83%. In the past year, price decreased by -27.78%.

Akers Biosciences / AKER Daily stock chart

AKER Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
AKER Full Technical Analysis Report

AKER Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AKER. While AKER has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AKER Full Fundamental Analysis Report

AKER Financial Highlights

Over the last trailing twelve months AKER reported a non-GAAP Earnings per Share(EPS) of -4.25. The EPS increased by 17.32% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -47.72%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%77.38%
Sales Q2Q%-100%
EPS 1Y (TTM)17.32%
Revenue 1Y (TTM)N/A
AKER financials

AKER Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
AKER Analyst EstimatesAKER Analyst Ratings

AKER Ownership

Ownership
Inst Owners6.24%
Ins Owners6.7%
Short Float %N/A
Short RatioN/A
AKER Ownership

About AKER

Company Profile

Akers Biosciences, Inc. develops, manufactures and supplies rapid, point-of-care screening and testing products. The Company's products primarily includes BreathScan(R), BreathScan PRO(R), METRON(R), VIVO(TM), Heparin/PF4 Antibody Serum Panels(R) and Breath Ketone. Akers Biosciences, Inc. is based in Thorofare, United States.

Company Info

Akers Biosciences

201 GROVE RD

THOROFARE NJ 08086

CEO: Christopher C. Schreiber

Phone: 856-848-8698

Akers Biosciences / AKER FAQ

What does Akers Biosciences do?

Akers Biosciences, Inc. develops, manufactures and supplies rapid, point-of-care screening and testing products. The Company's products primarily includes BreathScan(R), BreathScan PRO(R), METRON(R), VIVO(TM), Heparin/PF4 Antibody Serum Panels(R) and Breath Ketone. Akers Biosciences, Inc. is based in Thorofare, United States.


What is the stock price of Akers Biosciences today?

The current stock price of AKER is 2.47 null. The price decreased by -9.52% in the last trading session.


Does AKER stock pay dividends?

AKER does not pay a dividend.


What is the ChartMill technical and fundamental rating of AKER stock?

AKER has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy AKER stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AKER.


What is the market capitalization of AKER stock?

Akers Biosciences (AKER) has a market capitalization of 41.13M null. This makes AKER a Nano Cap stock.